Week in Review: The Latest from PhRMA

Medicare: Medicare celebrated its 50th anniversary this week! To note the occasion, we looked at the continued success of Part D, which helps many older Americans and people living with disabilities:
Read More
Celebrating Anniversaries: Americans with Disabilities Act

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Fact Check Friday: The Truth about IPR and Biopharmaceutical Patents

Today, we’re pleased to be kicking off our newest Catalyst blog series: Fact Check Friday. We’ll be using this space to separate truth from fiction and set the record straight when the rhetoric...
Read More
Happy 50th Anniversary Medicare!

Today we bring you a special edition of #MedicareMonday on Medicare’s 50th anniversary. As Medicare celebrates 50 years, we wanted to remind you about some of our Medicare resources and continue...
Read More
4 Things to Know about the Medicare Part D Premium Announcement

Today, the Centers for Medicare & Medicaid Services announced that average monthly premiums for Medicare Part D prescription drug coverage in 2016 will remain stable at an estimated $32.50 per month....
Read More
ICYMI: Community Oncologists Speak Out Against Hospital Cancer Doctors’ Drug Price Control Proposals

In case you missed it, the Community Oncology Alliance (COA) called the drug-price control recommendations made by 118 oncologists published in the journal Mayo Clinic Proceedings “misguided because...
Read More
3 Points You Need to Know about the Federal Government’s Health Spending Projections

New National Health Expenditure (NHE) projections released today by the Centers for Medicare & Medicaid Services (CMS) call into question claims that have been made in recent months about the...
Read More
New Study Examines Clinical Pathways: An Overview of Current Practices and Potential Implications for Patients, Payers, and Providers

As health care payers seek to transition to new, value-based payment models, clinical pathways are one strategy payers and providers are using in their efforts to contain costs and promote...
Read More
No Two Patients with High Cholesterol are the Same: Meet George and Betty

Last week, we introduced two hypothetical patients, Sheryl and Bill, who are working to get their cholesterol levels under control. Today we highlight George and Betty. George is able to control his...
Read More
Patient Groups, Members of Congress and Other State-Based Stakeholders Agree: Stop the Abuse of Biopharmaceutical Patents

As Congress considers patent legislation known as H.R. 9, the Innovation Act, and S. 1137, the PATENT Act, health care leaders – from patient groups to Members of Congress to trade associations –...
Read More
Medicare Monday: More Medicines in Development for Older Americans

This Thursday, Medicare celebrates its 50th anniversary! One critical part of Medicare for older Americans and people living with disabilities is the Part D prescription drug benefit that began in...
Read More
Biopharmaceutical Industry Strongly Committed to Responsible Clinical Trial Data Sharing to Improve Public Health

The biopharmaceutical industry remains committed to enhancing public health through responsible data sharing that recognizes the importance of protecting patient privacy, respects the integrity of...
Read More
Focusing on Only 1% of Spending Will Not Solve Nation’s Health Care Challenges

Commentary published today in Mayo Clinic Proceedings highlights a critical challenge facing cancer patients: the ability to access the medicines they need. But rather than address this issue...
Read More
I’m Not Average: Doreen’s Struggle with Cholesterol (Video)

After a heart attack at only 39 and subsequent diagnosis of high cholesterol, Doreen was in shock. “That was the beginning of a great challenge for me,” says Doreen. She knew she had to stay alive...
Read More
No Two Patients with High Cholesterol are the Same: Meet Sheryl and Bill

Even though Sheryl and Bill both have high cholesterol they have two very different stories. Sheryl is able to control her cholesterol level through statin therapy combined with lifestyle changes...
Read More
How many Americans could potentially be treated with new PCSK9 inhibitors? (Hint: It won’t be as many as critics claim)

Despite claims that tens of millions of Americans could be eligible for treatment with a new class of cholesterol-lowering medications, called PCSK9 inhibitors, the fact is these new medicines will...
Read More
Medicare Monday: New Research Finds Beneficiaries Live Longer After Implementation of Medicare Part D

New research published last week in the American Journal of Managed Care found reductions in mortality among Medicare beneficiaries following the implementation of Medicare Part D. We’ve talked...
Read More
Week in Review: The Latest from PhRMA

Neurological Disorders: America’s biopharmaceutical companies are committed to developing innovative new treatments for the nearly 50 million Americans affected by neurological disorders. This week,...
Read More
New Chart Pack: Biopharmaceuticals in Government Programs

Today, PhRMA released a new resource on biopharmaceuticals in government programs. This new chart pack features key facts about prescription medicines in four major government programs – Medicare,...
Read More
Medicine Spending Relatively Stable Following Increased Regulatory Data Protection in Canada and Japan

There has been much discussion about the effects of adding 12 years of data protection for biologics in the TPP. However, fears that this could add to the cost of healthcare seem to be unfounded. A ...
Read More
In Case You Missed It: Progress and Promise in Alzheimer’s Research

PhRMA recently convened a panel of health care experts for a live webcast discussion about the current state of research to treat and care for Alzheimer’s disease. Dr. Bill Chin of PhRMA moderated...
Read More
The War on Alzheimer’s: Progress and Challenges of Biopharmaceutical Research

Alzheimer’s disease steals memories, relationships and independence. It is a ruthless, devastating disease ravaging more than 5 million people in the United States alone, and is the sixth-leading...
Read More
Burden on Patients: Questions on Access to Cancer Medicines in Health Exchange Plans

Patients, especially those suffering from chronic conditions, deserve access to the medicines they need to live longer, healthier lives. Today, PhRMA released a new fact sheet on access to oncology...
Read More
Are new hep C treatments cost effective? Doctors say answer is “a resounding yes”

In case you missed it, a recent Bloomberg story features a new report from an influential panel of doctors and medical experts which finds that new treatments for hepatitis C are “cost effective.”...
Read More
New PhRMA and Epilepsy Foundation Report: 420 Medicines in Development for Neurological Disorders

It’s hard to imagine, but there are currently more than 50 million Americans – nearly one-sixth of our population – affected by some type of neurological disorder. While some of these are more...
Read More
Medicare Monday: New Video - How Patients Benefit from Medicare Part D

Today is the 5th White House Conference on Aging and later this month Medicare will celebrate its 50th birthday. To celebrate, we’re releasing a new video on how patients benefit from Medicare Part D.
Read More
Week in Review: The Latest from PhRMA

Healthy Outlook: The Cancer Support Community’s Rob Goldsmith highlighted a new report from his organization that found discrepancies in the definition of value in cancer care. July 15 Webcast Will...
Read More
CSC Survey Finds Discrepancy in Definition of Value in Cancer Care

A recent survey of 769 metastatic breast cancer patients found there is a significant discrepancy in the definition of value within cancer care. Conducted by the Cancer Support Community (CSC),...
Read More
Alzheimer’s disease has a devastating impact on patients, their loved ones and the caregivers who help them navigate their daily lives. It’s a particularly cruel disease – one that is especially...
Read More
New Infographic: Medicines Cut Health Care Costs

Retail prescription medicines account for just 10 percent of U.S. health care spending and are often the most cost-effective means of preventing and treating disease. A 2013 study by IMS Institute...
Read More
Biopharmaceutical Innovation Benefits Many Sectors of Industry

While the connection between sectors isn’t obvious to many, the sheet metal industry plays an integral role in the development of new medicines. Without it, many innovative new treatment options...
Read More
Medicare Monday: Celebrating Medicare

Welcome back to Medicare Monday and happy July! This is a big month for Medicare so we hope you’ll check back with us regularly as we celebrate some big occasions. Next Monday, July 13th, is the ...
Read More
Outdated FDA Regulations Discourage Development and Dissemination of Healthcare Economic Data to Support Value-Based Healthcare

As demand for evidence about the clinical and economic benefits of new treatments continues to grow, Food and Drug Administration (FDA) regulations on communications by biopharmaceutical companies...
Read More
ICYMI: New Report on Benefits of Cancer Medicines That Emerge After FDA Approval

In case you missed it, Boston Healthcare Associates recently published a report examining how additional benefits of cancer medicines emerge over time through ongoing research after initial approval...
Read More